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Abstract: Background: A single nucleotide polymorphism (SNP) of the Fat, Mass, and Obesity
associated (FTO) gene, rs9939609, is significantly associated with obesity [1] and individual
variability in weight loss achieved by diet/lifestyle interventions [13-18]. However, study results
on the effect of the FTO gene on weight loss remains inconsistent. This study aims to examine
the moderating effects of the FTO SNP rs9939609 on weight loss achieved by a lifestyle
intervention in breast cancer survivors. Methods: Breast cancer survivors with a body mass
index (BMI) > 25 kg/m2 were randomized to the LEAN 6-month intervention, which included
eleven 30-min counseling sessions focused on reducing caloric intake, increasing physical
activity and behavioral therapy or to a usual care group. Fasting blood was collected at baseline
and 6 months, with genotyping of the SNP rs9939609 using the Taqman® SNP genotyping
assay. The main effects of genotype and weight loss intervention on outcome changes were
analyzed using general linear models, with adjustment for age at baseline. Results: There were
30.4% of individuals with the wild-type TT genotype, 50% with AT- genotype, and 19.7% with
AA-genotype. No significant interaction between genotype and randomization group observed
for changes in weight, BMI, and total fat% (p = 0.945, 0.932, and 0.176, respectively). Weight
loss was higher in women in the intervention group, as compared to the usual care group (-4.8 vs
-0.6 kg, p < 0.001) and across all genotypes (p < 0.05). Weight changes did not significantly
differ among those with AA/AT or TT genotypes (p > 0.05). Conclusions: Genetic variation of
the FTO gene rs9939609 did not modify the effect of the weight-loss intervention on changes in
body weight. Women who are genetically predisposed to obesity and recently diagnosed with
breast cancer benefit from lifestyle changes similarly to women who are not genetically
predisposed to obesity. Our findings may help guide the incorporation of lifestyle interventions
and weight loss counseling into breast cancer survivorship care.
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Introduction
Breast cancer survival has significantly improved over the years because of
advancements in cancer treatment, early screening, and detection. Meanwhile, obesity has been
found to increase the risk of breast cancer recurrence and cancer-specific mortality in women [5].
In 2016, there were an estimated 3,560,570 female breast cancer survivors in the United States
[3] and over 65% of breast cancer survivors are either overweight or obese [4].
Recent guidelines from the American Cancer Society currently recommend breast cancer
survivors maintain a healthy weight by following a diet high in fruits, vegetables, and whole
grains and participate in at least 150 minutes of aerobic exercise and two sessions of strength
training per week[6]. However, fewer than 30% of breast cancer survivors follow the physical
activity guidelines and greater than 65% have a BMI ≥ 25[4].
The risk of obesity is driven by complex interactions of environmental, lifestyle, and
genetic factors [7]. One of the most widely-replicated obesity loci is the FTO protein located on
the FTO gene on chromosome 16 [1]. A meta-analysis of 21 studies reported significant
associations between the FTO gene SNP rs9939609 and obesity. Carriers of the obesity
predisposing A-allele had 1.31 odds of being obese compared to non-carriers for the wild-type T
allele [8]. Although the exact physiological function of the FTO gene remains unknown [9],
several studies have reported that obesity related variants of the FTO gene may play a role in
appetite regulation, body weight control, and fat intake [1, 10-12].
Genetic variability in obesity-associated genes may help explain why certain individuals
enrolled in lifestyle interventions are unable to lose weight compared to others. Several studies
have examined the role of the FTO gene on body weight changes achieved through diet and
lifestyle interventions [13-18]. A recent meta-analysis showed variation in the FTO SNP
rs9939609 may affect weight loss during diet/lifestyle intervention, where individuals carrying
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two A-risk alleles achieved more weight loss through diet/lifestyle interventions compared to
non-carriers (TT) [2].
To our knowledge, there are no studies assessing the moderating effect of the FTO
rs9939609 gene on weight loss and body composition achieved by diet/lifestyle interventions in
breast cancer survivors. Several studies have also reported on the association of rs9939609
polymorphism and increased risk of breast cancer [19, 20]; however, the results remain
inconsistent [36]. Thus, it is important to understand the influence of the FTO gene on weight
loss, specifically in breast cancer survivors due to the impact of obesity on the recurrence of
breast cancer and cancer-specific mortality in this population.
Methods
The Lifestyle, Exercise, and Nutrition (LEAN) study combined two 6-month Phase III
randomized-controlled weight loss intervention trials [21]. The LEAN 1 study was a three-arm
study examining the effect of usual care vs in-person or telephone counseling on 6-month
changes in diet, body composition, physical activity, and serum biomarkers in 100 women
treated for breast cancer. The LEAN 2 study was conducted to increase the sample size from
LEAN 1, but to also give women the option of in-person or telephone counseling since both
approaches to weight loss counseling were found to be effective in LEAN 1. Thus, LEAN 2 was
a two-arm trial of usual care vs. counseling (either via in-person or telephone or a combination of
in-person or telephone) in 51 women treated for breast cancer. Both LEAN 1 and LEAN 2
studies were combined for this analysis.
Weight loss intervention
The weight loss intervention in the LEAN study used a model which combined elements of
behavioral therapy, increased physical activity, and dietary changes in order to reduce overall
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BMI and body fat. The 6-month weight loss intervention consisted of a total of eleven 30-minute
individualized counseling sessions, which occurred weekly for the first month, bi-weekly for
months 2 and 3, and then monthly for months 4, 5 and 6.
Usual Care
Participants randomized to the usual care group received nutrition and physical activity
brochures from the American Institute for Cancer Research and a referral to the Yale Cancer
Center Survivorship Clinic, which offers two-session of a weight management program. After
the completion of the 6-month study, participants in the usual care group were offered all the
intervention materials and 11 counseling sessions.
Anthropometric measures
Participants were advised to only wear light indoor clothing, without shoes during the
height and weight measurements. Height was measured using a stadiometer and rounded to the
nearest 0.1 kg, and the weight measurements were done using a digital scale with weight
rounded to the nearest 0.1 kg. The measurements were recorded twice and averaged for analyses.
Body fat was assessed using Dual-Energy X-Ray Absorptiometry (DEXA) scans at
baseline and 6 months using the Hologic 4500 scanner. A Radiologic Technician certified in
bone density, and blinded to randomization group, evaluated all the scans.
Blood Draw
A fasting (≥12 hours) blood draw was taken at baseline and 6 months and processed and
stored at − 80 °C until analyses. . The laboratory technicians were also blinded to treatment
assignments.
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Genotyping
Genomic DNA was extracted from buffy-coat using MagNA Pure compact nucleic acid
isolation kit I (Roche, Indianapolis, IN) following the manufacturer's protocol. The concentration
and quality of DNA were determined using a Nano Drop 1000 spectrophotometer (Nano Drop
Tech, Wilmington, DE).
Genotyping of the FTO SNP (rs9939609) was performed using the TaqMan® SNP genotyping
assay (Applied Biosystems, Foster City, CA) following the manufacturer’s instructions. Briefly,
in a volume of 10 µl PCR reaction, 5 µl of 2× TaqMan genotyping master mix (Applied
Biosystem, CA) was mixed with pre-designed TaqMan® primers/probes (Applied Biosystems),
approximately 10–50ng of genomic DNA, and distilled water. The PCR conditions were initial
denaturing at 95°C for 10 min followed by 40 cycles of denaturing at 92°C for 15 s and
annealing/extension at 60°C for 1min. The reactions were carried out in an ABI 7500 Real-time
PCR System (Applied Biosystems). Ten percent of samples were run in duplicate for quality
control, with 100% concordance.
Statistical analysis
The Kolmogorov-Smirnov test was used to test for normality. Data were combined from
the LEAN 1 and 2 studies and differences in treatment groups were analyzed using the X2 test or
Fisher exact (for categorical variables) and the Mann-Whitney’s U-test (for numeric variables).
The X2 test was used to verify whether the allele frequencies of the FTO variant rs9939609 were
in Hardy-Weinberg equilibrium. Because the LEAN 1 and 2 study were conducted at different
times, we assessed for differences in baseline characteristics in LEAN 1 and 2 study participants
by randomization group.
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Genetic associations between baseline variables were analyzed with the additive (AA vs
AT vs TT) and dominant (AT+AA vs TT) model using the linear models, adjusting for age.
The main effects of genotype and weight loss intervention on outcome changes at 6
months were analyzed using general linear models, with adjustment for covariates including age.
To analyze the potential interactions between genotype and randomization group, the appropriate
cross product term was included in the regression models. Intervention effects are presented for
each genotype. Analyses were performed using SAS version 9.4 (Cary, NC). Power calculations
were performed using the QUANTO software version 1.2.4. Statistical significance was set at P
< .05 using two-sided tests.
Results
Characteristics of LEAN participants
Baseline characteristics of participants according to treatment arm are presented in Table
1. Participants in the combined LEAN studies (n=151) were predominantly non-Hispanic white
(91%), postmenopausal (83%), and highly educated, with 41% having earned a graduate degree.
Women in the intervention group were older than women in the usual care group (59.0 and 56.0
years, respectively; p < 0.001). A higher proportion of women in the intervention group were
taking an Aromatase inhibitor (AI) compared to the usual care group (25.6 % vs 18.8%; p =
0.06). Baseline body weight and BMI were found to be statistically significantly different
between the intervention and usual care group. As compared to the intervention group, the usual
care group started with a higher median initial body weight (82.4 kg vs 90.1 kg, p = 0.039) and
higher median baseline BMI (30.1 kg/m2 vs 33.3 kg/m2, p = 0.006).
There were 30.4% of individuals with the wild-type TT genotype, 50% with ATgenotype, and 19.7% with AA-genotype. The distribution of the genotype did not differ by
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treatment arm (p = 0.495). The genotypic distribution of the FTO SNP rs9939609 in the LEAN 1
and LEAN 2 study was in Hardy-Weinberg equilibrium (p=0.821, 0.811). At baseline, there were
no differences in baseline BMI and weight across genotype, as shown in Table 2. The FTO SNP
rs9939609 was observed to be not associated with baseline BMI in the regression model,
assuming a dominant mode of inheritance (p= 0.819).
Changes in Body Composition by LEAN study
In the combined LEAN studies (n=151), there were greater changes in weight loss, BMI,
and total body fat % in the intervention compared to the usual care group (p < 0.001) (Table 3).
Women in the intervention group lost an additional 4.3 kg (SE = 0.7, 95% CI: -5.7 – -2.9)
compared to the usual care group who lost 0.6 kg (SE=0.5, 95% CI: -1.7 – 0.4). The intervention
group achieved greater loss in BMI and total body fat (%) of 1.8 kg/m2 (SE=0.2, 95% CI: -2.2 – 1.5) and 3.9% (SE = 0.5%, 95% CI: -4.8 – -2.9) respectively, compared to the usual group who
achieved only 0.2 kg (SE: 0.2 95% CI: -0.6 – 0.2) and 0.1 % (SE: 0.8, 95% CI : -1.3 – 1.0),
respectively.
Changes in Body Composition by genotype variants of the FTO rs9939609
There was no significant interaction between genotype and randomization group
observed for changes in weight, BMI, and total body fat% (p = 0.945, 0.932, and 0.176,
respectively) (Table 3). Weight loss and changes in BMI were significantly higher in women in
the intervention group compared to the usual care group across all genotypes (Table 3).
In our stratified analysis within LEAN 1 and 2 study, we observed similar results by the
intervention group versus the usual care group and across all genotype variants (data not shown).

9

Discussion
Obesity is associated with poorer clinical outcomes in women with breast cancer [22-25]. There
has been an increased in research and community-based programs on lifestyle interventions to
help women with breast cancer maintain a healthier weight [21, 26]. Since the A-allele of the
FTO rs9939609 has a strong influence on body weight, our study aimed to examine the
moderating effects of the FTO SNP rs9939609 on weight loss achieved by lifestyle intervention
in breast cancer survivors.
To our knowledge, this is the first study to examine the genotypic effect on weight loss in this
population.
The six-month LEAN intervention led to an average weight loss of 4.8 kg in the
intervention group, compared to 0.6 kg weight loss in the usual care group. Because a recent
meta-analysis reported that individuals who have the AA genotype may lose more weight
through diet and lifestyle intervention compared to individuals with the TT genotype [2], we
hypothesized women who are carriers of the A-risk allele to achieve greater weight loss
compared to non-carriers [2].
However, significant weight loss was achieved in both carriers of the FTO risk allele and
among non-carriers in the intervention group.
Although we did not observe any effect of the genetic variation on weight loss or BMI,
our findings further support previous studies demonstrating no genetic influences of the FTO
SNP rs9939609 on weight loss induced by lifestyle interventions of diet and/or exercise
interventions [17, 27-29]. An explanation for this finding may be attributed to the fact that
physical activity and diet changes may attenuate the effect of the FTO gene on body weight [30].
In our study, baseline body weight and BMI were not associated with the FTO genotype.
Although the differences were not significant, women who had two A-risk alleles had a higher
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baseline body weight and BMI compared to the other groups. More specifically, women who
carried one A-risk allele had a lower baseline body weight compared to the non-carriers (TT
genotype). Our findings were inconsistent as previously reported studies have reported a higher
BMI among those who are carriers of the A-risk allele compared to non-carriers[1, 10, 31]. An
explanation for this finding may be due to our study eligibility criteria. Women were only
eligible for enrollment in our study if they had a BMI of ≥ 25. Our strict selection criteria may
have limited our ability to detect any significant association between the FTO gene and BMI, as
previous studies have included participants with varying BMI levels[1, 28]. Despite the lack of
association between the FTO genotype and BMI, significant weight loss was achieved across all
genotype variants.
In addition, it is well understood that the risk for obesity is multifactorial and polygenic
[32]. The FTO gene has been associated with regulating appetite and energy expenditure [1, 1012] however, the precise mechanism of the FTO gene remains unknown. A limitation of our
study is that we only examined one SNP, which may limit our ability to assess for any
association between other variants within the FTO region. Previous studies have also reported
several FTO SNPs (r17817449, rs3751812, rs1421085, rs993056, and rs7202116) are associated
with obesity [1, 33-35]. Thus, further studies are needed to assess more FTO variants and their
potential role in the regulation of the expression of other genes responsible for weight loss.
Furthermore, there are several additional limitations to our study. First, weight and total
body fat measures were not collected on 23 of the 151 women enrolled, and our results are
limited to mostly non-Hispanic white women and highly educated women. Second, in our post
hoc power calculations, we found that we were underpowered to detect any interaction between
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genotype and randomization group on changes in weight, BMI, and total body fat (power: 5%,
5%, and 25%, respectively). However, we did find similar weight losses between FTO genotype.
In conclusion, our study found that the genetic variation of the FTO rs9939609 did not
modify the effect of the intervention on weight loss. These findings suggest that individuals who
are genetically predisposed to obesity may achieve weight loss despite being carriers of the Arisk allele. The variation in the FTO gene has no influence on changes in body weight and BMI
after lifestyle modifications. Women who are genetically predisposed to obesity and recently
diagnosed with breast cancer may benefit from lifestyle changes. Our findings may help guide
the incorporation of lifestyle interventions and weight loss counseling into breast cancer
survivorship care.
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Table 1: Baseline characteristics of study participants in LEAN 1 and LEAN 2
TOTAL (LEAN 1 + 2 )
Characteristic

Age, years, median (IQR)
Postmenopausal, n (%)
White n (%)
Education, n (%)
High school degree
Some college
College degree
Graduate degree
Time from diagnosis to LEAN enrollment,
years, median (IQR)
Body weight (kg), median (IQR)
Baseline BMI*, kg/m2, median, (IQR)
BMI category, n (%)
Overweight (25≤ BMI<30)
Obese (BMI  30)
Disease stage, n (%)
0
1
2
3

Total
N = 151

Intervention
N=93

Control
N =58

58.0
(52.0 –64.0)
126 (83.4)
136 (91.3)

59.0
(54.0 – 64.0)
79 (85.0)
87 (94.6)

56.0
(49.0 –61.0)
47 (81.0)
49 (86.0)

19 (12.6)
39 (25.8)
30 (19.9)
63 (41.7)

10 (10.8)
22 (23.7)
23 (24.7)
38 (40.9)

9 (15.5)
17 (29.3)
7 (12.1)
25 (43.1)

2.2
(1.3 – 3.5)
84.2
(74.7– 98.5)
31.2
(28.2 –36.6)

2.3
(1.4 – 3.4)
82.4
(71.4– 91.5)
30.1
(27.7–35.4)

2.1
(1.2–4.5)
90.1
(75.8 –104.0)
33.3
(29.1– 39.1)

60 (40.0)
90 (60.0)

44(47.3)
49(52.7)

16(28.1)
41(71.9)

25 (16.9)
75 (50.7)
37 (25.0)
11 (7.4)

13 (14.3)
47(26.7)
23(25.3)
8(8.8)

12(21.1)
28 (49.1)
14(24.6)
3(5.3)

17 (11.3)
58 (38.4)
24 (15.9)
52 (34.4)

8(8.6)
35 (37.6)
18 (19.4)
32 (34.4)

9(10.3)
23 (40.0)
6 (10.3)
20(34.5)

30 (23.1)
43 (33.1)
10 (7.7)
47 (36.2)

21 (25.6)
20(24.4)
7(8.5)
34 (41.5)

9(18.8)
23(47.9)
3(6.3)
13 (27.1)

19 (20.9)
42 (46.2)
30 (33.0)
61 (67.0)
30 (33.0)

10 (17.5)
32 (56.1)
15 (26.3)
42 (73.7)
15 (26.3)

LEAN 1
P1

<0.001
0.529
0.071

0.260

LEAN 1
Treatment
N=67

LEAN 1
Control
N=33

60
(54.0– 65.0)
56 (83.6)
63 (95.5)

57.0
(53.0–63.0)
26 (78.8)
30 (90.9)

9(13.4)
14(20.9)
16 (23.9)
28 (41.8)

5 (15.2)
6 (18.2)
4 (12.1)
18 (54.6)

0.545
80.6
(75.0– 108.5)
31.1
(28.5–38.8)

0.020

30(44.8)
37 (55.2)

13 (39.4)
20 (60.6)

0.662

9 (13.9)
33 (50.8)
18 (27.7)
5 (7.7)

6(18.8)
18 (52.6)
6 (18.6)
2 (6.3)

8 (11.9)
23(34.3)
18 (26.9)
18 (26.9)

7 (21.2)
13 (39.4)
4 (12.1)
9 (27.3)

15 (26.3)
11 (19.3)
5 (8.8)
26 (45.6)

6 (26.1)
12 (52.2)
2 (8.7)
3 (13.0)

11 (16.9)
32 (49.2)
22 (33.9)
43 (66.2)
22(33.9)

18 (54.6)
7 (21.2)
8 (24.2)
25(75.8)
8(24.2)

0.006

Int. 1 vs 2

Ctr. 1 vs 2

P3

P4

P5

0.128

0.239

0.256

0.703
0.239

0.750
0.619

0.742
0.261

0.223

0.477

0.135

0.333

0.182

0.622

0.001

0.393

0.066

0.009

0.693

0.189

3 (12.5)
21(87.5)

0.002

0.432

0.026

4 (15.4)
14 (53.9)
5 (19.2)
3 (11.5)

6(24.0)
10 (40.0)
8 (32.0)
1 (4.0)

0.433

0.825

0.557

0
12 (46.2)
0
14 (53.9)

2 (8.0)
10 (40.0)
2 (8.0)
11 (44.0)

0.210

0.002

0.393

6 (24.0)
9 (36.0)
2 (8.0)
8 (32.0)

3 (12.0)
11 (44.0)
1 (4.0)
10 (40.0)

0.625

0.421

0.167

8 (30.8)
10 (38.5)
8 (30.8)
18 (69.2)
8 (30.8)

3 (12.5)
14 (58.3)
7 (29.2)
17(70.8)
7 (28.2)

0.231

0.329

0.682

0.902

0.778

0.677

LEAN 2
Control
N=25

57.5
(54.0–63.0)
23 (88.5)
24 (92.3)

55.0
(48.0–59.0)
21 (84.0)
19 (79.2)

1 (3.9)
8 (30.8)
7 (26.9)
10 (38.5)

4 (16.0)
11 (44.0)
7 (26.9)
7 (28.0)

1.8
(1.1–3.1)
77.1
(71.1–88.0)
29.1
(26.9–35.4)

1.9
(1.4–5.1)
93.9
(87.9–102.2)
35.8
(32.3–39.1)

0.609

14(53.9)
12(46.2)

0.750

P2

0.353
0.557
0.397

0.487

0.832
82.6
(74.0–92.1)
30.1
(28.8– 35.6)

0.039

LEAN 2
LEAN 2
Intervention
N=26

0.523
0.290

Adjuvant post-surgery treatment, n (%)
None
Radiation only
Chemotherapy only
Both
Endocrine therapy*, n (%)
Aromatase inhibitors (AIs) only
Tamoxifen only
Tamoxifen and AIs
None
FTO genotype rs9939609
(T>A) n, (%)
Additive model
AA
AT
TT
Dominant
AT + AA
model
TT

29(19.6)
74(50.0)
45 (30.4)
103 (69.6)
45 (30.4)

0.337

0.055

0.495
0.392

0.307

0.012

0.607
0.330

Note: Percentages may not sum to 100% due to rounding or missing values. Data presented as numbers with percentages in parentheses, or median and interquartile range (IQR) in brackets. P values from chi-square
test or fisher exact test for categorical data and Wilcoxon rank sum tests for median values.
P1:P-value of intervention vs control in combined LEAN studies; P2: P-value of intervention vs control in LEAN 1 study; P3: P-value of intervention vs control in LEAN 2 study; P4: P-value comparing
the intervention groups between LEAN 1 and 2 study; P5: P-value comparing the control groups between LEAN 1 and 2 study.
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Table 2: Weight profiles and key biometrics of combined LEAN study participants by FTO SNP rs9939609 (T>A)

Variable

Baseline Body weight (kg)
Mean (SE)
(95% CI)
Baseline BMI (kg/m2),
Mean (SE)
(95% CI)

AA
n=30

AT
n=74

TT
n=45

89.9 (3.3)

87.2 (2.1)

88.1 (2.7)

(83.4 – 96.4)

(83.1 – 91.3)

(82.9 – 93.3)

35.0 (1.2)

32.6 (0.8)

32.9 (1.0)

(32.6 – 37.4)

(31.2 – 34.1)

(31.1 – 34.8)

Additive model
p-value

Dominant model
p-value

0.350

0.224

0.350

0.819

Note: Percentages may not sum to 100% due to rounding or missing values.
Data presented least square means and 95% CI in brackets.
P-values from general liner model for mean values. Adjusted for age.
Abbreviations: BMI: Body Mass Index, CI: Confidence interval, SE: Standard error
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Table 3: Changes in weight, body mass index (BMI), total fat % by group and FTO rs9939609 genotype (T>A)
Outcome

Group

Intervention

Control

Effect Size

P-value

-4.8 (0.4) [-5.7– -3.9]

-0.6 (0.5) [-1.7– 0.4]

-4.3 (0.7) [-5.7 – -2.9]

<0.001

AA+AT

-4.5 (0.6) [-5.6 – -3.4]

-0.3 (0.7) [-1.6 – 1.0]

-4.2 (0.9) [-5.9 – 2.5]

<0.001

TT

-5.5 (0.8) [-7.1 – -4.0]

-1.2 (1.0) [-3.3 – 0.8]

-4.3 (1.3) [-6.9 – -1.8]

0.001

Combined LEAN 1 + 2
Δ Weight (kg)
Mean * (SE) [95% CI]

P-value for genotype x group = 0.945 Model was adjusted for age *Least square means from model Differences of Least Square Means

Outcome

Group

Intervention

Control

Effect Size

P-value

-1.8 (0.2) [-2.2 – -1.5]

-0.2 (0.2) [-0.6 – 0.2]

-1.6 (0.3) [-2.2 – -1.1]

<0.001

AA+AT

-1.7 (0.2) [-2.1 – -1.3]

-0.1 (0.3) [-0.6 – 0.4]

-1.6 (0.3) [-0.4 – 1.1]

<0.001

TT

-2.1 (0.3) [-2.7 – -1.5]

-0.4 (0.4) [-1.2 – 0.3]

-1.6 (0.5) [-2.6 – -0.7]

0.001

Combined LEAN 1 + 2
Δ BMI

(kg/m2)

Mean* (SE) [95% CI]

P-value for genotype x group = 0.932 Model was adjusted for age *Least square means from model Differences of Least Square Means

Outcome

Group

Intervention

Control

Effect Size

P-value

-3.9 (0.5) [-4.8 – -2.9]

-0.1 (0.8) [-1.3 – 1.0]

-3.7 (0.8) [-5.3 – =2.2]

<0.001

AA+AT

-3.7 (0.6) [-4.9 – -2.5]

-0.7 (0.7) [-2.1 – 0.7]

-3.0 (0.9) [-4.8 – -1.1]

0.002

TT

-4.1 (0.8) [ -5.8 – -2.5]

1.1 (1.1) [-1.1 – 3.4]

-5.3 (1.4) [-8.0 – - 2.5]

0.003

Combined LEAN 1 + 2
Δ Total Fat (%)
Mean (SE) [95%CI]

P-value for genotype x group = 0.176 Model was adjusted for age *Least square means from model Differences of Least Square Means
Note: Percentages may not sum to 100% due to rounding or missing values.
Data presented least square means and 95% CI in brackets; P-values from general liner model for mean values and adjusted for age.
Abbreviations: BMI: Body Mass Index, CI: Confidence interval, SE: Standard error

15

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.

Frayling, T.M., et al., A common variant in the FTO gene is associated with body mass index and predisposes to childhood and
adult obesity. Science, 2007. 316(5826): p. 889-94.
Xiang, L., et al., FTO genotype and weight loss in diet and lifestyle interventions: a systematic review and meta-analysis. The
American journal of clinical nutrition, 2016. 103(4): p. 1162-1170.
Miller, K.D., et al., Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin, 2016. 66(4): p. 271-89.
Jiralerspong, S., et al., Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann
Oncol, 2013. 24(10): p. 2506-14.
Chan, D., et al., Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of
82 follow-up studies. Annals of Oncology, 2014. 25(10): p. 1901-1914.
Rock, C.L., et al., Nutrition and physical activity guidelines for cancer survivors. CA: a cancer journal for clinicians, 2012.
62(4): p. 242-274.
van der Klaauw, A.A. and I.S. Farooqi, The hunger genes: pathways to obesity. Cell, 2015. 161(1): p. 119-132.
Peng, S., et al., FTO gene polymorphisms and obesity risk: a meta-analysis. BMC Med, 2011. 9: p. 71.
Reference, G.H. FTO gene. 2019; Available from: https://www.ncbi.nlm.nih.gov/pubmed/.
Mei, H., et al., FTO influences on longitudinal BMI over childhood and adulthood and modulation on relationship between
birth weight and longitudinal BMI. Hum Genet, 2010. 128(6): p. 589-96.
Church, C., et al., Overexpression of Fto leads to increased food intake and results in obesity. Nat Genet, 2010. 42(12): p.
1086-92.
Tanofsky-Kraff, M., et al., The FTO gene rs9939609 obesity-risk allele and loss of control over eating. Am J Clin Nutr, 2009.
90(6): p. 1483-8.
de Luis, D.A., et al., The rs9939609 gene variant in FTO modified the metabolic response of weight loss after a 3-month
intervention with a hypocaloric diet. Journal of Investigative Medicine, 2013. 61(1): p. 22-26.
McCaffery, J., et al., FTO predicts weight regain in the Look AHEAD clinical trial. International Journal of Obesity, 2013.
37(12): p. 1545.
Woehning, A., et al., The A-allele of the common FTO gene variant rs9939609 complicates weight maintenance in severe
obese patients. International journal of obesity, 2013. 37(1): p. 135.
Verhoef, S.P., et al., Genetic predisposition, dietary restraint and disinhibition in relation to short and long-term weight loss.
Physiology & behavior, 2014. 128: p. 247-251.
Grau, K., et al., Macronutrient-specific effect of FTO rs9939609 in response to a 10-week randomized hypo-energetic diet
among obese Europeans. Int J Obes (Lond), 2009. 33(11): p. 1227-34.
Mitchell, J.A., et al., FTO genotype and the weight loss benefits of moderate intensity exercise. Obesity, 2010. 18(3): p. 641643.

16

19.
20.
21.

22.
23.
24.
25.
26.
27.
28.
29.

30.
31.
32.
33.
34.
35.

Kaklamani, V., et al., The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. BMC Med Genet,
2011. 12: p. 52.
Kusinska, R., et al., Influence of genomic variation in FTO at 16q12.2, MC4R at 18q22 and NRXN3 at 14q31 genes on breast
cancer risk. Mol Biol Rep, 2012. 39(3): p. 2915-9.
Harrigan, M., et al., Randomized trial comparing telephone versus in-person weight loss counseling on body composition and
circulating biomarkers in women treated for breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. Journal of
Clinical Oncology, 2016. 34(7): p. 669.
Donegan, W., A. Hartz, and A. Rimm, The association of body weight with recurrent cancer of the breast. Cancer, 1978.
41(4): p. 1590-1594.
Donegan, W., et al., The prognostic implications of obesity for the surgical cure of breast cancer. Breast, 1978. 4(4): p. 14-17.
Boyd, N.F., et al., Body weight and prognosis in breast cancer. Journal of the National Cancer Institute, 1981. 67(4): p. 785789.
Tartter, P.I., et al., Cholesterol and obesity as prognostic factors in breast cancer. Cancer, 1981. 47(9): p. 2222-2227.
Basen-Engquist, K., et al., Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivors. Patient
education and counseling, 2006. 64(1-3): p. 225-234.
Franks, P.W., et al., Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes
Prevention Program. Diabetologia, 2008. 51(12): p. 2214-23.
Haupt, A., et al., Impact of variation in the FTO gene on whole body fat distribution, ectopic fat, and weight loss. Obesity
(Silver Spring), 2008. 16(8): p. 1969-72.
Muller, T.D., et al., 'Fat mass and obesity associated' gene (FTO): no significant association of variant rs9939609 with weight
loss in a lifestyle intervention and lipid metabolism markers in German obese children and adolescents. BMC Med Genet,
2008. 9: p. 85.
West, N.R., et al., Effect of Obesity-Linked FTO rs9939609 Variant on Physical Activity and Dietary Patterns in Physically
Active Men and Women. J Obes, 2018. 2018: p. 7560707.
Lappalainen, T.J., et al., The common variant in the FTO gene did not modify the effect of lifestyle changes on body weight: the
Finnish Diabetes Prevention Study. Obesity (Silver Spring), 2009. 17(4): p. 832-6.
Loos, R.J. and A.C.J. Janssens, Predicting polygenic obesity using genetic information. Cell metabolism, 2017. 25(3): p. 535543.
Scuteri, A., et al., Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related
traits. PLoS genetics, 2007. 3(7): p. e115.
Hinney, A., et al., Genome wide association (GWA) study for early onset extreme obesity supports the role of fat mass and
obesity associated gene (FTO) variants. PloS one, 2007. 2(12): p. e1361.
Yang, J., et al., FTO genotype is associated with phenotypic variability of body mass index. Nature, 2012. 490(7419): p. 267.

17

36.

Jafari Nedooshan, Jamal et al. “Lack of Association of the Fat Mass and Obesity Associated (FTO) Gene rs9939609
Polymorphism with Breast Cancer Risk: a Systematic Review and Meta-Analysis Based on Case - Control Studies.” Asian
Pacific journal of cancer prevention : APJCP vol. 18,4 1031-1037. doi:10.22034/APJCP.2017.18.4.1031

18

